PPAR-delta activation ameliorates obesity and insulin resistance [59], and has been considered as a potential therapeutic target in treatment of lipid-related disorders, including dyslipidemia and diabetes [60, 61]. Here, PPARD is linked to obesity due to melanocortin 4 receptor deficiency.